Skip to main content
Top
Published in: Endocrine Pathology 3/2010

01-09-2010

Features of Papillary Thyroid Microcarcinoma in the Presence and Absence of Lymphocytic Thyroiditis

Authors: Hee Sung Kim, Yoon Jung Choi, Ji-Sup Yun

Published in: Endocrine Pathology | Issue 3/2010

Login to get access

Abstract

It is known that the prevalence of lymphocytic thyroiditis (LT) is higher in patients with papillary thyroid carcinoma (PTC), that gender influences this association, and that certain features of PTC occur more frequently in patients who also have LT. These relationships have not been studied in patients with papillary thyroid microcarcinomas (PTMC), however. Therefore, we performed a study to compare the clinical and pathological features of patients with PTMC who did and did not have LT. We collected the 323 consecutive patients following excision of PTMC diagnosed as papillary carcinoma on preoperative needle aspiration cytology. We analyzed the demographic, serologic, and pathologic data of those cases with categorization into four groups based on presence of LT and neck lymph node metastasis. In all PTMC, the presence of LT did not influence the frequency of lymph node metastasis (27 of 105 [25.7%] vs. 48 of 218 [22.0%]). Among the patients with metastatic PTMC, LT was noted significantly more often in female than male patients (95.2% vs. 79.8%). In metastatic PTMC, multifocality and bilaterality was more frequent in with LT than without LT (44.4% vs. 29.2%; 29.6% vs. 14.6%). Both the presence of serum thyroglobulin antibody (TgAb; p = 0.016) and serum microsomal antibody (p = 0.013) were highly correlated with the presence of LT. Twenty-seven of 105 patients (25.7%) with PTMC with LT had nodal metastasis. Co-existing LT was noted predominantly in women, influenced more often multifocality and bilaterality of tumors, and higher frequency of metastasis to lateral compartment lymph nodes.
Literature
1.
go back to reference Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70(2):291–297, 1955.PubMed Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70(2):291–297, 1955.PubMed
2.
go back to reference Matsubayashi S et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 80(12):3421–3424, 1995.CrossRefPubMed Matsubayashi S et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 80(12):3421–3424, 1995.CrossRefPubMed
3.
go back to reference Kashima K et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8(3):197–202, 1998.CrossRefPubMed Kashima K et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8(3):197–202, 1998.CrossRefPubMed
4.
go back to reference Singh B et al. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 126(6):1070–1076, 1999; discussion 1076–7.CrossRefPubMed Singh B et al. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 126(6):1070–1076, 1999; discussion 1076–7.CrossRefPubMed
5.
go back to reference Asanuma K et al. The relationship between multiple intrathyroidal involvement in papillary thyroid carcinoma and chronic non-specific thyroiditis. Cancer Lett 122(1–2):177–180, 1998.CrossRefPubMed Asanuma K et al. The relationship between multiple intrathyroidal involvement in papillary thyroid carcinoma and chronic non-specific thyroiditis. Cancer Lett 122(1–2):177–180, 1998.CrossRefPubMed
6.
go back to reference Repplinger D et al. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150(1):49–52, 2008CrossRefPubMed Repplinger D et al. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150(1):49–52, 2008CrossRefPubMed
7.
go back to reference Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev 31(6):423–438, 2005.CrossRefPubMed Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev 31(6):423–438, 2005.CrossRefPubMed
8.
go back to reference Falvo L et al. Papillary microcarcinoma of the thyroid gland: analysis of prognostic factors including histological subtype. Eur J Surg Suppl (588):28–32, 2003. Falvo L et al. Papillary microcarcinoma of the thyroid gland: analysis of prognostic factors including histological subtype. Eur J Surg Suppl (588):28–32, 2003.
9.
go back to reference DeLellis RA, LR, Heitz PU et al. eds. WHO: Pathology and Genetics. Tumours of Endocrine Organs. 2004, Lyon, France: IARC Press. DeLellis RA, LR, Heitz PU et al. eds. WHO: Pathology and Genetics. Tumours of Endocrine Organs. 2004, Lyon, France: IARC Press.
10.
go back to reference Roti E et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 91(6):2171–2178, 2006.CrossRefPubMed Roti E et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 91(6):2171–2178, 2006.CrossRefPubMed
11.
go back to reference Pacini F et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh) 119(3):373–380, 1988. Pacini F et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh) 119(3):373–380, 1988.
12.
go back to reference Baloch Z et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13(1):3–126, 2003.CrossRefPubMed Baloch Z et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13(1):3–126, 2003.CrossRefPubMed
13.
go back to reference Loh KC et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84(2):458–463, 1999.CrossRefPubMed Loh KC et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84(2):458–463, 1999.CrossRefPubMed
15.
go back to reference Kim SK et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 19(2):137–141, 2009.CrossRefPubMed Kim SK et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 19(2):137–141, 2009.CrossRefPubMed
Metadata
Title
Features of Papillary Thyroid Microcarcinoma in the Presence and Absence of Lymphocytic Thyroiditis
Authors
Hee Sung Kim
Yoon Jung Choi
Ji-Sup Yun
Publication date
01-09-2010
Publisher
Springer US
Published in
Endocrine Pathology / Issue 3/2010
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-010-9124-9

Other articles of this Issue 3/2010

Endocrine Pathology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine